Home › Compare › NBIO vs JNJ

NBIO vs JNJ: Dividend Comparison 2026

NBIO yields 666666.67% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBIO wins by $8.275235618773884e+34M in total portfolio value
10 years
NBIO
NBIO
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full NBIO calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — NBIO vs JNJ

📍 NBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBIOJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBIO + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
NBIO pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBIO
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, NBIO beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBIO + JNJ for your $10,000?

NBIO: 50%JNJ: 50%
100% JNJ50/50100% NBIO
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NBIO
No analyst data
Altman Z
-223.9
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBIO buys
0
JNJ buys
0
No recent congressional trades found for NBIO or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBIOJNJ
Forward yield666666.67% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$8.275235618773884e+34M$20.0K ✓
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00 ✓$827.78
Total dividends collected$8.275075881065991e+34M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NBIO vs JNJ ($10,000, DRIP)

YearNBIO PortfolioNBIO Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$66,677,367$66,666,666.67$10,676$355.77+$66.67M → NBIO
2$415,506,651,117$415,435,306,334.37$11,407$389.39+$415506.64M → NBIO
3$2,419,908,598,386,268$2,419,464,006,269,573.00$12,198$426.53+$2419908598.37M → NBIO
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$13,056$467.62+$13171697643084.44M → NBIO
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$13,987$513.12+$67004927492790120.00M → NBIO
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$14,998$563.56+$318562277003514871808.00M → NBIO
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$16,098$619.52+$1.415484168853553e+24M → NBIO
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$17,295$681.69+$5.878130573362507e+27M → NBIO
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$18,599$750.82+$2.2813793009840744e+31M → NBIO
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$20,022$827.78+$8.275235618773884e+34M → NBIO

NBIO vs JNJ: Complete Analysis 2026

NBIO — Stock

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Full NBIO Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this NBIO vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBIO vs SCHDNBIO vs JEPINBIO vs ONBIO vs KONBIO vs MAINNBIO vs ABBVNBIO vs MRKNBIO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.